Ionis Pharmaceuticals, Inc. Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31)
Ionis Pharmaceuticals, Inc. (IONS) reported Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) of 1.3 Y for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition · last filed 2012-02-29
- 2011-06-30: Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 6 month 130.00%.
pure
| Period end | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 6 month |
|---|---|
| 2011-06-30 | 130.00% 10-Q · filed 2011-08-08 |
Y
| Period end | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 9 month | Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition (Deprecated 2012-01-31) 12 month |
|---|---|---|
| 2011-12-31 | 1.30 Y 10-K · filed 2012-02-29 | |
| 2011-09-30 | 1.30 Y 10-Q · filed 2011-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |